Voyager Therapeutics, Inc. (NASDAQ:VYGR) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 1,346,882 shares, a growth of 44.9% from the October 13th total of 929,333 shares. Approximately 10.2% of the company’s shares are short sold. Based on an average daily volume of 413,483 shares, the short-interest ratio is currently 3.3 days.
Shares of Voyager Therapeutics (VYGR) opened at $13.60 on Monday. Voyager Therapeutics has a 12-month low of $8.10 and a 12-month high of $25.99.
A number of equities research analysts have recently issued reports on VYGR shares. Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, August 8th. Stifel Nicolaus initiated coverage on shares of Voyager Therapeutics in a research report on Friday, July 28th. They set a “buy” rating and a $20.00 price target for the company. Canaccord Genuity initiated coverage on shares of Voyager Therapeutics in a research report on Friday, October 27th. They set a “buy” rating and a $35.00 price target for the company. ValuEngine raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Finally, Chardan Capital reissued a “hold” rating on shares of Voyager Therapeutics in a research report on Sunday, September 10th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. Voyager Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $28.89.
In other news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total value of $54,900.00. Following the completion of the sale, the insider now owns 17,157 shares of the company’s stock, valued at approximately $171,570. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 32,940 shares of company stock valued at $490,092 in the last ninety days. 8.00% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN raised its holdings in Voyager Therapeutics by 312.8% in the 3rd quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock worth $7,766,000 after purchasing an additional 285,806 shares in the last quarter. Citadel Advisors LLC bought a new position in Voyager Therapeutics in the 3rd quarter worth $5,155,000. JPMorgan Chase & Co. bought a new position in Voyager Therapeutics in the 3rd quarter worth $270,000. SG Americas Securities LLC bought a new position in Voyager Therapeutics in the 3rd quarter worth $577,000. Finally, Bank of New York Mellon Corp raised its holdings in Voyager Therapeutics by 16.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 61,858 shares of the company’s stock worth $1,274,000 after purchasing an additional 8,633 shares in the last quarter. Institutional investors and hedge funds own 40.94% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/11/13/voyager-therapeutics-inc-vygr-short-interest-up-44-9-in-october.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.